Union Health Ministry has proposed amendments to Drugs Rules, 1945 to mandate Authorisation of qualified personnel for drug batch release

1. At a Glance

• The Union Ministry of Health and Family Welfare (MoHFW) has published a draft amendment to the Drugs Rules, 1945. Every drug manufacturer would have to formally name a suitably qualified and experienced person who is authorised to release each batch [1].
• Manufacturers would also have to keep prescribed records for every batch, and a standard Batch Release Certificate format would be added to the Rules [1].
• Why it matters: batch release is the last quality check before a drug reaches the market. Naming one person for it fixes accountability, makes each decision traceable and supports GMP compliance [1].
• UPSC angle: It falls under GS-II (health, regulatory bodies) and GS-III (pharmaceutical industry). It is part of a series of drug-quality reforms that followed the cough-syrup contamination episodes [5][8].

2. Why in the News

• 03 Nov 2026: PIB reported that MoHFW has proposed amendments to the Drugs Rules, 1945 that require an authorised person for batch release, batch-release records and a Batch Release Certificate [1].
• The amendment was published as a draft notification in the Official Gazette, and objections and suggestions have been invited [1].
• Comments go to the Under Secretary (Drugs Regulation), MoHFW, by post or email [1].

3. Background & Evolution

• Drugs and Cosmetics Act, 1940: the parent law. The Rules, dated 21 December 1945, are made under it [6][9].
• The existing rule on holding batches: the licensing authority can tell a licensee not to sell a batch whose samples or test protocols it has asked for. The licensee must wait until the authority issues a certificate authorising sale [6]. This is a decision by the regulator, not by someone inside the company.
• 28 Dec 2023: G.S.R. 922(E) revised Schedule M, which sets the GMP requirements and the rules for premises, plant and equipment for pharmaceutical products. It added a Pharmaceutical Quality System, Quality Risk Management, and Qualification & Validation [2].
• 28 Jun 2024: the revised Schedule M became binding on large manufacturers (turnover above ₹250 crore) [3].
• 2024: CDSCO and the State Drugs Controllers carried out risk-based inspections of 400 premises, including MSMEs [2].
• Feb 2025: smaller manufacturers (turnover of ₹250 crore or less) got a conditional extension to 31 Dec 2025 to comply with the revised Schedule M [3].
• Late 2025: after the cough-syrup quality concerns, the Union Health Secretary chaired a meeting with States and UTs on the quality and rational use of cough syrups [8].
• 29 Dec 2025: G.S.R. 927(E) withdrew the exemption that allowed cough syrups to be sold in small villages without a licensed pharmacy. They must now be sold through licensed pharmacies only [5].
• 2026: formulations with more than 12% v/v ethyl alcohol, in quantities above 30 mL, lost their Schedule K exemption and were moved under Schedule H1 [4].
• 03 Nov 2026: the draft amendment on batch release discussed in this note [1].

4. Core Static Facts

Item	Fact
Batch release	Final stage of manufacturing: an overall review of the quality parameters and documents before a batch is distributed [1]
Authorised person (proposed)	Suitably qualified and experienced person whom the manufacturer formally designates to release batches. Licence applicants must name this person [1]
Current licensing gap	Licences require details of competent technical staff for manufacturing and testing, but there is no provision to name the person who releases batches [1]
New documents	(i) batch-release records for every batch; (ii) a prescribed Batch Release Certificate format [1]
Proposing body	MoHFW, Drugs Regulation division [1]
Parent law	Drugs and Cosmetics Act, 1940 → Drugs Rules, 1945 [6]
GMP schedule	Schedule M, revised by G.S.R. 922(E) dated 28.12.2023 [2]
Schedule M timeline	Turnover above ₹250 cr: from 28 Jun 2024. Turnover of ₹250 cr or less: conditionally extended to 31 Dec 2025 [3]
Central regulator	Central Drugs Standard Control Organisation (CDSCO), which works with the State Drugs Controllers [2]
International benchmark	WHO GMP defines the "authorized person" as the person the national regulator recognises as responsible for ensuring that each batch of finished product is manufactured, tested and approved for release in line with the law [7]
Stage	Draft. Objections and suggestions invited; not yet final [1]

5. Multi-Dimensional Analysis

Legal / Regulatory

• This is subordinate legislation: rules under the 1940 Act, amended by Gazette notification after a public-comment window [1][6].
• It adds to the existing power of the licensing authority to hold batches until it certifies them [6]. The new layer places in-house accountability on a named person, alongside the regulator's external control.
• It turns into law the WHO GMP idea of an authorised person who answers for every batch [7].

Governance / Ethical

• It replaces diffuse responsibility shared across "technical staff" with one named person who answers for the decision [1].
• Records and a standard certificate create an audit trail, so the regulator can trace a failed batch back to the person who released it [1].
• Ethical aspect: professional accountability for public safety, similar to a "duty of care" owed by a certifying professional.

Economic / Industry

• India's export reputation depends on matching WHO-GMP expectations. A defined release role [7] supports market access.
• MSMEs face extra compliance costs, including hiring qualified people, keeping records and building systems. The repeated Schedule M extensions for smaller firms show the industry has limited capacity to absorb this [3].

Social / Public Health

• It acts as a final barrier against substandard or contaminated batches reaching patients. This is relevant given the cough-syrup episodes [5][8].
• It supports the right to health (Art. 21, as interpreted by the courts) through better drug quality assurance.

Administrative

• Enforcement depends on State Drugs Controllers and CDSCO inspections [2]. Unless inspection capacity improves, the named-person rule could remain a paper formality.
• The new rule needs to fit with the Pharmaceutical Quality System and validation requirements of the revised Schedule M [2].

6. Recent Developments (last 12-18 months)

• 29 Dec 2025: G.S.R. 927(E) withdrew the cough-syrup sale exemption for small villages [5].
• 31 Dec 2025: deadline (conditionally extended) for smaller manufacturers to comply with the revised Schedule M [3].
• 2025: high-level meeting chaired by the Union Health Secretary with States and UTs on cough-syrup quality [8].
• 2026: amendment moving formulations with high alcohol content (more than 12% v/v, above 30 mL) from Schedule K to Schedule H1 [4].
• 03 Nov 2026: draft batch-release amendment published for comments [1].

7. Prelims Hooks

• The draft amendment proposes that manufacturers formally authorise a qualified person for batch release [1].
• Applicants for a manufacturing licence must name the authorised person [1].
• The draft adds a prescribed Batch Release Certificate format to the Drugs Rules, 1945 [1].
• Manufacturers must keep records for every batch manufactured [1].
• Batch release is the final stage of pharmaceutical manufacturing [1].
• Comments go to the Under Secretary (Drugs Regulation), MoHFW [1].
• The Drugs Rules, 1945 are made under the Drugs and Cosmetics Act, 1940 [6].
• Schedule M of the Drugs Rules covers Good Manufacturing Practices [2].
• The revised Schedule M was notified by G.S.R. 922(E) dated 28 December 2023 [2].
• The revised Schedule M applied to firms with turnover above ₹250 crore from 28 June 2024 [3].
• Firms with turnover of ₹250 crore or less got a conditional extension to 31 December 2025 [3].
• G.S.R. 927(E) (29 Dec 2025) limited cough-syrup sales in small villages to licensed pharmacies [5].
• Formulations with more than 12% v/v alcohol and above 30 mL moved from the Schedule K exemption to Schedule H1 [4].
• CDSCO and the State Drugs Controllers inspected 400 premises in a risk-based drive [2].
• In WHO GMP, the "authorized person" is recognised by the national regulatory authority [7].

8. Who Does the Authorised Person Really Answer To?

• The person who signs off is paid by the company whose batch they judge
• Under the draft, the manufacturer itself formally names the authorised person [1].
• In WHO GMP (Good Manufacturing Practice, the international rulebook for making medicines safely), the authorised person is someone the national regulator recognises [7].

• So in India the company picks the gatekeeper, while in the WHO model the regulator stands behind that choice. If the person refuses to release a batch, nothing in the draft as reported protects their job [1].

• The draft says "qualified", but not "independent"

• PIB describes the person only as "suitably qualified and experienced" [1].
• WHO guidance says production and quality control (QC, the lab testing of samples) must run under separately named people who are independent of each other [10].

• If the authorised person worked on making or testing a batch, WHO says they cannot release that same batch [10]. Without this rule, a person can end up approving their own work.

• Release is treated as a signature, not a duty that lasts after the batch leaves the factory

• WHO makes the authorised person responsible for carrying out and coordinating recalls (pulling a faulty batch back from the market) [7].
• The PIB release talks about records and a certificate. It does not say the authorised person leads a recall when a released batch later fails [1].
• So the trail now leads to a named person, but nothing in the draft says what that person must do once the trail is followed.

9. A Signature Is Only as Strong as the Inspector Who Checks It

• The rule relies on inspectors that States do not have
• A batch-release record only matters if a drug inspector reads it, or tests the drug on the market.
• CAG found an 88% vacancy in Karnataka's drugs inspector cadre. Lab supervisor posts were 56% vacant and lab technician posts 75% vacant [11].

• In Punjab, only 52 of the 120 drug inspectors required were in post in March 2015 [12].

• Test results arrive after patients have already taken the medicine

• In the Karnataka audit, 59% of drugs were already used up before their test results came back [11].
• In Punjab, reports for 12,971 of 18,146 samples tested in 2010–15 took between 30 days and one year [12].

• So even if a batch is found NSQ (Not of Standard Quality: it fails the official quality test), the regulator learns this too late to stop harm. The audit trail then only helps fix blame afterwards.

• The shortage is old, and reports on it keep repeating

• The Mashelkar Committee had already asked for more drug inspectors with better skills [14].
• In 2026, the Parliamentary Standing Committee on Health still pointed to persistent vacancies among Drugs Controllers that slow CDSCO's work. It also said CDSCO's generalist administrative set-up cannot handle complex technical evaluation [13].
• The Centre reports more than 960 risk-based inspections since December 2022 [15]. That is real progress, but small against the number of licensed units across India.

10. The Case That This Is Just One More Form

• The strongest objection
• Firms already have to employ technical staff for manufacturing and testing [1]. Adding one more signature and one more certificate does not, by itself, test a single extra sample.

• Smaller firms are still struggling with the revised Schedule M, and needed a deadline extension to 31 Dec 2025 [3]. A new named post adds cost before the old reform has fully taken hold.

• What is right about it

• Without independence rules [10] and inspectors to check the records [11][12], the certificate can turn into a formality signed at the end of the day.

• Why the rule still matters

• Today, when a batch fails, blame is spread across "technical staff" in general [1]. A named signatory changes the incentive: one person now has their own name on the decision.
• WHO GMP treats this person as the final barrier: no batch may be sold until the authorised person certifies it [7]. India's export markets expect this role, so the rule closes a gap with them.
• The fair conclusion is that the rule is necessary but not enough. It works only if it is paired with the fixes below.

11. What Should Change Before the Draft Becomes Final

• MoHFW should write independence into the final rule
• Bar the authorised person from releasing any batch they helped make or test, as WHO guidance does [10].

• Some countries go further and require one authorised person from production and one from QC to release a batch jointly [10]. India could start with this for high-risk products such as oral liquids.

• CDSCO should keep a record of who the authorised persons are

• WHO's model is that the regulator recognises the person [7]. A central list would let CDSCO see when the same person signs for a failed batch more than once, even across companies.

• The final rule should link the certificate to recalls

• When a batch is declared NSQ, the Batch Release Certificate [1] should automatically identify who released it. The authorised person should then lead the recall, as WHO GMP requires [7].

• States and the Centre should fill inspector and lab posts on a fixed timeline

• The Standing Committee asked for Drugs Controller vacancies to be filled on a time-bound basis, for a specialist cadre inside CDSCO, more empanelled testing labs and mandatory training for State inspectors [13].
• Without this, the vacancies CAG found [11] mean the new records are kept but never read.

12. Anchors for Answers

• Data: 88% of drugs inspector posts vacant in Karnataka, and 59% of drugs consumed before their test results arrived (CAG Report No. 8 of 2024) [11]
• Data: Only 52 of 120 required drug inspectors in post in Punjab, March 2015 (CAG) [12]
• Data: 960+ risk-based inspections of manufacturing units since December 2022 [15]
• Report/Committee: Mashelkar Committee, which called for more and better-trained drug inspectors [14]. Parliamentary Standing Committee on Health and Family Welfare (2026), which called for filling Drugs Controller vacancies on a fixed timeline and creating a specialist cadre in CDSCO [13]
• Law/Case: Drugs and Cosmetics Act, 1940 → Drugs Rules, 1945, including Schedule M (GMP) [2][6]. Article 21 (right to health, as read by the courts)
• Comparison: WHO GMP: the authorised person is recognised by the national regulator, must certify every batch before sale, and leads recalls [7]. In some countries, production and QC authorised persons release a batch jointly [10]

13. Mains Relevance

• GS-II: Issues relating to the development and management of Health; Statutory, regulatory and quasi-judicial bodies; Government policies and interventions.
• GS-III: Indian economy and industry (the pharmaceutical sector, MSMEs).
• GS-IV: Accountability and ethical governance; professional responsibility.
• Possible question stems: 1. Recent amendments to the Drugs Rules, 1945 seek to shift drug quality assurance from regulator-led control to manufacturer accountability. Critically examine. (GS-II, 15 marks) 2. India is called the 'pharmacy of the world', but repeated drug-quality failures have damaged its credibility. Discuss the regulatory reforms undertaken and the gaps that remain. (GS-II/III, 15 marks) 3. Fixing individual accountability is central to ethical governance in public-health regulation. Illustrate with reference to pharmaceutical batch release. (GS-IV, 10 marks)

14. Related Topics to Study Next

• Revised Schedule M (2023): the GMP framework this amendment is meant to strengthen [2].
• CDSCO and State Drugs Controllers: they share enforcement in a dual Centre–State structure [2].
• Cough-syrup contamination and the regulatory response: the immediate reason behind the quality-tightening series [5][8].
• Schedules H, H1, K and X: the drug classification system that is often amended [4][6].
• WHO GMP and the WHO prequalification of medicines: international benchmarks for the authorised-person concept [7].
• The proposed new Drugs, Medical Devices and Cosmetics law: a long-pending overhaul of the 1940 Act.
• The Production Linked Incentive (PLI) scheme for pharmaceuticals: the industrial-policy side of drug quality and exports.

15. NCERT Concepts to Revise

• Accountability (Polity): The draft's core aim is naming one person who answers for each batch release decision.
• Delegated legislation (Polity): The amendment changes Drugs Rules made by the executive under the 1940 Act, after public comments.
• Right to health (Polity): Drug quality assurance is tied to the right to health under Article 21.
• Comptroller and Auditor General (Polity): CAG audits of Karnataka and Punjab show inspector vacancies and delayed drug test results.
• Standing committee (Polity): The 2026 Parliamentary Standing Committee on Health flagged Drugs Controller vacancies and CDSCO's weak technical capacity.
• Production-linked incentive (Economy): The PLI scheme for pharmaceuticals is the industrial-policy side of drug quality and exports.

16. Common Errors / Trap Areas

• Draft vs final: this is a proposed amendment open for objections. It is not yet notified as final [1].
• Act vs Rules: Schedule M and the batch-release provisions sit in the Rules (1945), not the Act (1940) [2][6].
• Name of the Rules: recent PIB releases say "Drugs Rules, 1945" [1][4][5], while India Code uses "Drugs and Cosmetics Rules, 1945" [6]. Both refer to the same base rules.
• Two different certificates: the new Batch Release Certificate is issued by the manufacturer's authorised person [1]. The licensing authority's certificate authorising sale of a withheld batch is issued by the regulator [6].
• Technical staff vs authorised person: licences already required technical staff for manufacturing and testing. The new role covers the release decision [1].
• Schedule M thresholds: the dividing line is ₹250 crore turnover. The 28 Jun 2024 start date applies to large firms only [3].